Posts

Summit reports two‑year survival data for Western patients, though context lacking

on
Summit Therapeutics has reported updated two-year overall survival (OS) data for Western patients in its HARMONi Phase III trial of ivonescimab plus chemotherapy in EGFR-mutated non–small cell lung cancer (NSCLC). At a June 2026 data cutoff, the Western subgroup showed an OS hazard ratio of 0.76 with a median follow‑up of 23.2 months, indicating a 24% reduction in the risk of death compared with placebo plus chemotherapy. The improvement in the Western HR over earlier analyses (from 0.98 in April 2025 to 0.84 in September 2025 and now 0.76) reflects longer follow‑up that better captures the full survival benefit. Median OS for Western patients treated with ivonescimab plus chemotherapy was approximately 16.8–17.0 months versus 14.0 months in the control arm, though detailed median OS, confidence intervals, and p‑values are reserved for an upcoming medical meeting. Sources: UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up Summit debuts longer-term ivonesci...

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

Biopharma Bites: 白宮AI挑戰、Mentari新資金、Royalty Pharma與Neurimmune交易

on

Arrowhead’s plozasiran posts strong hypertriglyceridemia data, sharpening race with Ionis

on

Crystalys Raises $130M Series B to Advance Gout Drug Dotinurad Through Phase 3

on

Trump floats countdown to 200% tariffs on generic drugs imported to US

on

How the FDA is unwinding the Makary era and making way for a new commissioner (2026 update)

on

Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on

on

Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill

on

Gilead and Merck Release Key HIV Data

on

Agios second shot at sickle cell disease falls short

on

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Samsung launches AI-powered Health Assistant to decode health data

on